This clinical trial evaluates lymph node mapping in newly diagnosed endometrial cancer patients undergoing surgery. The standard technique uses a 2-point methylene blue cervical injection. The study aims to determine if increasing injection points improves mapping success.
Individuals diagnosed with stage I endometrial cancer based on CT and PET-CT imaging.
Individuals with a pathologically confirmed diagnosis of stage I endometrial cancer.
Individuals diagnosed with dementia.
Individuals with allergies to methylene blue or iodine.
Individuals who have received active treatment for another malignancy within the past five years.
Inability to successfully perform PLD (pelvic lymphadenectomy) or history of prior PLD.